LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・CytoSorbents Corp

CytoSorbents Corp

Затворен

СекторЗдравеопазване

0.44 2.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.43

Максимум

0.45

Ключови измерители
By Trading Economics
Приходи	368K -5.1M
Продажби	-370K 8.9M
EPS	-0.08
Марж на печалбата	-57.863
Служители	129
EBITDA	648K -3M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+63.04% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-9.5M 30M
Предишно отваряне	-1.89
Предишно затваряне	0.44

Настроения в новините

By Acuity

46%

54%

135 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

0.705 / 0.771 Подкрепа & съпротива

CytoSorbents Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21.05.2026 г., 16:49 ч. UTC

Печалби

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21.05.2026 г., 16:26 ч. UTC

Значими двигатели на пазара

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21.05.2026 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164M

21.05.2026 г., 21:53 ч. UTC

Печалби

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21.05.2026 г., 21:02 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21.05.2026 г., 20:55 ч. UTC

Печалби

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21.05.2026 г., 20:30 ч. UTC

Горещи акции

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Adj EPS 3c >BULL

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Rev $159.9M >BULL

21.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Easing in Early May -- Market Talk

21.05.2026 г., 20:18 ч. UTC

Печалби

Webull 1Q Loss/Shr 4c

21.05.2026 г., 19:43 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21.05.2026 г., 18:58 ч. UTC

Печалби

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21.05.2026 г., 18:15 ч. UTC

Пазарно говорене

Gold Higher For Second Consecutive Day -- Market Talk

21.05.2026 г., 17:40 ч. UTC

Пазарно говорене

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21.05.2026 г., 17:04 ч. UTC

Пазарно говорене

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21.05.2026 г., 17:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Stellantis Targets Distant but Constructive -- Market Talk

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

CytoSorbents Corp Прогноза

Ценова цел

By TipRanks

63.04% нагоре

12-месечна прогноза

Среден 0.75 USD 63.04%

Висок 0.75 USD

Нисък 0.75 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за CytoSorbents Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на CytoSorbents Corp през последните 3 месеца.

Техническа оценка

By Trading Central

0.705 / 0.771Подкрепа & съпротива

All events are bearish.

Настроение

By Acuity

135 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.